Cargando…

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death while leaving normal cells intact. Apart from the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rajani, Karishma R., Vile, Richard G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664987/ https://www.ncbi.nlm.nih.gov/pubmed/26580645 http://dx.doi.org/10.3390/v7112914

Ejemplares similares

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
por: Chauhan, Sachin Kumar Singh, et al.
Publicado: (2020)

Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
por: Rajani, Karishma R., et al.
Publicado: (2019)

Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
por: Jiang, Jingyu, et al.
Publicado: (2023)

Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers
por: Acebes-Fernández, Vanessa, et al.
Publicado: (2020)

Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy
por: Fatima, Shadma, et al.
Publicado: (2022)

Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants
por: Willows, Steven, et al.
Publicado: (2020)

Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy
por: El-Kadiry, Abed El-Hakim, et al.
Publicado: (2022)

Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors
por: Kim, Nayoung, et al.
Publicado: (2021)

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
por: Bedard, Melissa, et al.
Publicado: (2017)

Harnessing the power of dividing cardiomyocytes
por: Muralidhar, Shalini A., et al.
Publicado: (2013)

Natural killer cells in liver transplantation: Can we harness the power of the immune checkpoint to promote tolerance?
por: Halma, Jennifer, et al.
Publicado: (2021)

Cancer immunotherapy beyond immune checkpoint inhibitors
por: Marin-Acevedo, Julian A., et al.
Publicado: (2018)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Harnessing the Microbiome to Enhance Cancer Immunotherapy
por: Nelson, Michelle H., et al.
Publicado: (2015)

Vaccine Vectors Harnessing the Power of Cytomegaloviruses
por: Ynga-Durand, Mario Alberto, et al.
Publicado: (2019)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
por: De Felice, Francesca, et al.
Publicado: (2015)

Harnessing the antitumor potential of macrophages for cancer immunotherapy
por: Long, Kristen B, et al.
Publicado: (2013)

Harnessing immunological targets for COVID-19 immunotherapy
por: Mehata, Abhishesh Kumar, et al.
Publicado: (2021)

Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
por: Yan, Liang, et al.
Publicado: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Harnessing the power of the Grid
Publicado: (2009)

Harnessing tumor-associated macrophages as aids for cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2019)

Harnessing Antitumor CD4(+) T Cells for Cancer Immunotherapy
por: Ben Khelil, Myriam, et al.
Publicado: (2022)

Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer
por: Hannon, Gary, et al.
Publicado: (2023)

Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy
por: Sulsenti, Roberta, et al.
Publicado: (2023)

Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment
por: Dobosz, Paula, et al.
Publicado: (2022)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy
por: Miao, Keyan, et al.
Publicado: (2023)

Extracellular vesicles in onco-nephrology
por: Gai, Chiara, et al.
Publicado: (2019)

Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
por: Gu, Yuanzhuo, et al.
Publicado: (2023)

Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy
por: Hino, Christopher, et al.
Publicado: (2023)

Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications
por: Hughes, Robert M., et al.
Publicado: (2020)

OncoSim and OncoWiki: an authentic learning approach to teaching cancer genomics
por: Schoenborn, Priska, et al.
Publicado: (2019)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmr16b85jsk7a3ft2gsg2639g2